Arrowhead Research Corporation (ARWR)

Oncology Corporate Profile

Stock Performance

5.9400
-0.0700

HQ Location

225 South Lake Avenue, 3rd Floor
Pasadena, 91101

Company Description

Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. The Company has clinical programs in small RNA therapeutics and obesity. Arrowhead's programs are based on its proprietary drug development and delivery platforms, each capable of creating multiple therapeutic products. This strategy seeks to enhance the return potential for investors and reduce risk compared to traditional biotech companies. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to optimize therapeutic agents for a wide range of diseases.

Website: http://www.arrowheadresearch.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
cyclosert / CRLX-101topoisomerase I inhibitorNon Small Cell Lung Cancer (NSCLC)IICerulean Pharma, Inc.
CALAA-01RNAi therapeuticVarious cancer typesICalando Pharmaceuticals
cyclosert / CRLX-101topoisomerase I inhibitorVarious cancer typesPreclinicalTube Pharma
UnnamedRNA antagonist (HIF-1 alpha antagonist)Various cancer typesResearch

View additional information on product candidates here »

Source: http://www.arrowheadresearch.com/

Recent News Headlines

7/20/2017 06:17 pm

7/20/2017 06:17 pm

7/20/2017 06:17 pm

7/20/2017 06:17 pm

7/10/2017 12:17 pm

7/10/2017 12:17 pm

7/10/2017 12:17 pm

7/10/2017 12:17 pm

6/9/2017 12:17 pm

6/9/2017 12:17 pm

6/9/2017 12:17 pm

6/9/2017 12:17 pm

6/9/2017 12:17 pm

5/6/2017 06:17 pm

5/6/2017 06:17 pm

5/6/2017 06:17 pm

5/6/2017 06:17 pm

5/6/2017 06:17 pm

5/5/2017 06:17 am

5/4/2017 12:17 pm

4/26/2017 12:17 pm

4/19/2017 12:17 pm

4/12/2017 06:17 am

Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement

3/23/2017 11:03 am

[Business Wire] - Arrowhead Pharmaceuticals Inc. today announced that on March 21, 2017 it entered into a stockholder rights agreement in accordance with an authorization and declaration from its board of directors of a dividend distribution of one preferred share purchase right on each outstanding share of the company’s common stock.